Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics to $58 from $55 and keeps a Buy rating on the shares. The analyst believes the initial 2023 guidance meets the bar set by most investors and sets up potential upward revisions throughout the year and we believe valuation levels should expand further as the company executes on its long-term growth strategy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG:
- 10x Genomics reports Q4 EPS (15c), consensus (31c)
- 10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
- Singular Genomics showcases G4 sequencing data with 11 genomics partners
- Singular Genomics joins 10x Genomics Compatible Partner Program
- 10x Genomics initiated with a Neutral at UBS
